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Sirolimus-
Paclitaxel Comparison
Lower Restenosis Rates in Small Vessels With Sirolimus Stents
Whereas the restenosis rates are known to be higher for bare-metal stents insmaller vessels, the relationship between vessel size and restenosis for drug-
eluting stents is less clear. Elezi and colleagues randomized over 2,000 patients under-
going elective percutaneous coronary intervention to either sirolimus-eluting stents
(SES) or paclitaxel-eluting stents (PES). The rates of target lesion revascularization
(TLR) after 6- and 9-month angiographic follow-up were then compared based on
initial vessel size. The rate of TLR was similar regardless of vessel size for SES, and was
similar betweenSES andPES for vessels2.4mm.However, for vessels2.4mm, the
rate of TLR was twice as high with PES versus SES. This study suggests that for most
interventions, the choice of SES or PES is one of operator preference, but SES appears
superior to PES for small vessels. See page 1304. See figure.
Intervention in
Acute Coronary Syndromes
Meta-Analysis Confirms That Early Invasive Strategy Reduces Mortality
Although some contemporary studies have found mortality benefits with an earlyinvasive strategy inpatientswith acute coronary syndromes, others have shownno
benefit, and older studies suggested increased hazards. In this meta-analysis that
included 7 large trials with over 8,000 patients, there was a 25% reduction in all-cause
mortality and a17%reduction innon-fatalmyocardial infarctionwith an early invasive
strategy. There was also a 31% reduction in rehospitalization for unstable angina. This
analysis suggests that managing acute coronary syndromes with an early invasive
strategy improves long-term survival without increasing early adverse events when
compared with an ischemia-driven protocol. See page 1319.
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Intervention in
Acute Coronary Syndromes
Improved Clinical Outcomes With Higher Clopidogrel Loading Doses
Although several studies have shown that a 600-mg loading dose of clopidogrelresults inmore platelet inhibition than a 300-mg dose, there has been a paucity of
data on clinical outcomes. Cuisset and colleagues randomized subjects with acute
coronary syndromes to either 300- or 600-mg loading doses of clopidogrel. Subjects
then underwent percutaneous coronary intervention at least 12 h later. Blood was
collected to determine adenosine diphosphate-induced platelet reactivity prior to
percutaneous coronary intervention.Thehigher loadingdose reduced the likelihoodof
high platelet reactivity (15% vs. 25%); this also correlated with better 30-day clinical
outcomes. This study demonstrates that a 600-mg loading dose for patients with acute
coronary syndromes results inmore complete platelet inhibition and improved clinical
outcomes. See page 1339. See figure.
(continued) A-39Page 1366
Percutaneous
Valve Prosthesis
Novel Design of Endovascular Valve
Allows for Repositioning After Deployment
Oneconcern with previously published reports of endovascular valve replacementis the inability to reposition the valve once it has been deployed. Zegdi and
colleagues describe a novel design where a porcine stentless valve is mounted on a
self-expanding nitinol stent and is passed through a sheath. The stent is compressed or
expanded via 2 sutures that can bemanipulated through the sheath. In an experimental
protocol, the valve was safely delivered and adequately positioned or repositioned in 5
sheep. This novel stent design allows percutaneous valves to be positioned and reposi-
tioned, which should improve the success rates for endovascular valve repair proce-
dures. See page 1365. See figure.
Heart Failure
Famotidine as a Novel Therapy for CHF
Recent evidence has suggested that histaminemay have depressed effects on cardiacfunction. The H2 histamine receptor is known to be a Gs-coupled receptor that
signals through cAMP, a pathway similar to that of cardiac beta-adrenoceptors. Kim
and colleagues hypothesized that an H2 receptor blocker may have salutary effects
similar to beta-blockers. In both a retrospective chart review and a prospective placebo-
controlled study, famotidine was associated with decreased plasma levels of brain
natriuretic peptide, improved New York Heart Association functional class, and
improved echocardiographic parameters. Larger studies will be needed to confirm that
famotidine is a simple and effective treatment for chronic heart failure, with a mecha-
nism similar to beta-blockers. See page 1378.
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Heart Rhythm Disorders
“Indeterminate” T-Wave Alternans Studies Are High Risk
Themicrovolt T-wave alternans (MTWA) test, which uses a graded exercise studyto look for alterations in the polarity of T-wave repolarization, has been proposed
as a potential discriminator of patients at highor low risk for sudden cardiac death.One
of this test’s main pitfalls has been a high rate of “indeterminate” results. Kaufman and
colleagues reviewed over 500MTWA tests with clinical follow-up.Nearly one-third of
tests were classified as “indeterminate”; patients with “indeterminate” test results had
mortality rates at least as high as those with positive results. In over 80% of tests with
indeterminate results, the reasonwas patient-related (either frequent ectopy during the
test or an inability to achieve and sustain a heart rate 105 beats/min). This report
lends further credence to the argument that “indeterminate” tests should be considered
“abnormal,” and that MTWA is useful as a discriminator between high- and low-risk
sub-groups. See page 1399. See figure.
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Pregnancy Safe for Females With LQT1 Mutations
Patients with LQT1 mutations have prolonged QTc at rest and may developventricular arrhythmias during vigorous exercise or emotional stress. This is due to
impairment in the IKs current, which disrupts the normal ability to shorten ventricular
repolarization as heart rate increases. Thus, any condition that augments sympathetic
activitymay lead to life-threatening arrhythmias, and there has been concern about the
safety of pregnancy in these individuals.Heradien and colleagues studied the outcomes
of pregnancies in 22 families with known LQT1 mutations. There were 3 (2.6%)
cardiac events (2 cardiac arrests) in the 115 LQT1 pregnancies; all occurred in females
with previous symptoms who were not taking beta-blocker therapy. The authors
conclude that for patients with no previous symptoms, pregnancy is safe. For those
with previous symptoms, beta-blocker therapy may reduce the likelihood of cardiac
events and appears safe for the fetus. See page 1410.
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Orthostatic Hypotension
Compressive Bandages Are Effective
for Progressive Orthostatic Hypotension
P rogressive orthostatic hypotension occurs in elderly people with prolongedstanding and can be quite debilitating; the currently available therapies
have limited efficacy or are relatively contraindicated in elderly patients with
comorbidities. Podoleanu and colleagues studied the use of leg and abdominal
compression stockings in both a sham-controlled tilt table test and in real-life
scenarios. The stockings were effective in preventing tilt table-induced symp-
toms and decreasing blood pressure. The stockings were well tolerated, with
significant decreases in the Specific Symptom Scale Questionnaire for Ortho-
static Intolerance. These bandages may be a simple and effective therapy for
progressive orthostatic hypotension. See page 1425. See figure.
